<p>(Adds share moves)</p>.<p>March 8 (Reuters) - Opko Health Inc said on Wednesday it signed a deal with Merck Co Inc potentially worth up to $922.5 million for its experimental Epstein-Barr virus vaccine.</p>.<p>Shares of Opko jumped 28% in premarket trade.</p>.<p>Merck will take over the clinical and regulatory activities related to the vaccine, as well its commercialization once the drugmaker files a joint application with Opko unit ModeX Therapeutics to test it in humans, the company said.</p>.<p>Opko will receive an upfront payment of $50 million and is eligible for milestone payments of up to $872.5 million, plus royalties on global sales.</p>.<p>There is currently no vaccine for the Epstein-Barr virus, which is the leading cause of mononucleosis, or mono, commonly called the "kissing disease". (Reporting by Aditya Samal in Bengaluru; Editing by Pooja Desai)</p>.<div><p><strong>ತಾಜಾ ಮಾಹಿತಿ ಪಡೆಯಲು <a href="https://t.me/Prajavani1947">ಪ್ರಜಾವಾಣಿ ಟೆಲಿಗ್ರಾಂ ಚಾನೆಲ್</a> ಸೇರಿಕೊಳ್ಳಿ</strong></p><p><strong>ತಾಜಾ ಸುದ್ದಿಗಳಿಗಾಗಿ ಪ್ರಜಾವಾಣಿ ಆ್ಯಪ್ ಡೌನ್ಲೋಡ್ ಮಾಡಿಕೊಳ್ಳಿ: <a href="https://play.google.com/store/apps/details?id=com.tpml.pv">ಆಂಡ್ರಾಯ್ಡ್ ಆ್ಯಪ್</a> | <a href="https://apps.apple.com/in/app/prajavani-kannada-news-app/id1535764933">ಐಒಎಸ್ ಆ್ಯಪ್</a></strong></p><p><strong>ಪ್ರಜಾವಾಣಿ <a href="https://www.facebook.com/prajavani.net">ಫೇಸ್ಬುಕ್ ಪುಟವನ್ನು</a>ಫಾಲೋ ಮಾಡಿ.</strong></p></div>
<p>(Adds share moves)</p>.<p>March 8 (Reuters) - Opko Health Inc said on Wednesday it signed a deal with Merck Co Inc potentially worth up to $922.5 million for its experimental Epstein-Barr virus vaccine.</p>.<p>Shares of Opko jumped 28% in premarket trade.</p>.<p>Merck will take over the clinical and regulatory activities related to the vaccine, as well its commercialization once the drugmaker files a joint application with Opko unit ModeX Therapeutics to test it in humans, the company said.</p>.<p>Opko will receive an upfront payment of $50 million and is eligible for milestone payments of up to $872.5 million, plus royalties on global sales.</p>.<p>There is currently no vaccine for the Epstein-Barr virus, which is the leading cause of mononucleosis, or mono, commonly called the "kissing disease". (Reporting by Aditya Samal in Bengaluru; Editing by Pooja Desai)</p>.<div><p><strong>ತಾಜಾ ಮಾಹಿತಿ ಪಡೆಯಲು <a href="https://t.me/Prajavani1947">ಪ್ರಜಾವಾಣಿ ಟೆಲಿಗ್ರಾಂ ಚಾನೆಲ್</a> ಸೇರಿಕೊಳ್ಳಿ</strong></p><p><strong>ತಾಜಾ ಸುದ್ದಿಗಳಿಗಾಗಿ ಪ್ರಜಾವಾಣಿ ಆ್ಯಪ್ ಡೌನ್ಲೋಡ್ ಮಾಡಿಕೊಳ್ಳಿ: <a href="https://play.google.com/store/apps/details?id=com.tpml.pv">ಆಂಡ್ರಾಯ್ಡ್ ಆ್ಯಪ್</a> | <a href="https://apps.apple.com/in/app/prajavani-kannada-news-app/id1535764933">ಐಒಎಸ್ ಆ್ಯಪ್</a></strong></p><p><strong>ಪ್ರಜಾವಾಣಿ <a href="https://www.facebook.com/prajavani.net">ಫೇಸ್ಬುಕ್ ಪುಟವನ್ನು</a>ಫಾಲೋ ಮಾಡಿ.</strong></p></div>
